Van Berkom & Associates Inc. Purchases 48,906 Shares of Globus Medical, Inc. $GMED

Van Berkom & Associates Inc. increased its position in Globus Medical, Inc. (NYSE:GMED) by 3.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,333,111 shares of the medical device company’s stock after purchasing an additional 48,906 shares during the quarter. Globus Medical makes up 2.2% of Van Berkom & Associates Inc.’s portfolio, making the stock its 22nd biggest position. Van Berkom & Associates Inc. owned 0.99% of Globus Medical worth $76,347,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in GMED. EverSource Wealth Advisors LLC grew its position in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares during the period. Advisors Asset Management Inc. bought a new position in Globus Medical in the second quarter valued at approximately $28,000. First Horizon Corp bought a new position in Globus Medical in the third quarter valued at approximately $31,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Globus Medical during the 3rd quarter worth $36,000. Finally, CENTRAL TRUST Co bought a new stake in shares of Globus Medical during the 2nd quarter valued at $39,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Stock Performance

Shares of GMED stock opened at $87.39 on Wednesday. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40. The company’s 50 day moving average price is $90.04 and its two-hundred day moving average price is $72.11. The company has a market capitalization of $11.70 billion, a P/E ratio of 28.19, a price-to-earnings-growth ratio of 1.38 and a beta of 1.06.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, November 6th. The medical device company reported $1.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.39. The company had revenue of $769.05 million during the quarter, compared to the consensus estimate of $734.58 million. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The firm’s revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.83 earnings per share. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. Analysts forecast that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on GMED shares. Wall Street Zen upgraded Globus Medical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 3rd. Zacks Research cut Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 9th. BTIG Research reaffirmed a “neutral” rating on shares of Globus Medical in a research note on Tuesday, December 30th. Piper Sandler reiterated an “overweight” rating and issued a $115.00 price target (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Finally, Canaccord Genuity Group boosted their price objective on shares of Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $100.18.

Insider Transactions at Globus Medical

In other Globus Medical news, CFO Kyle Kline sold 3,594 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $363,353.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Kelly Huller sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $90.00, for a total value of $675,000.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 91,636 shares of company stock worth $7,984,583. 18.54% of the stock is currently owned by company insiders.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.